23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®), and Pembrolizumab (Keytruda®)
23ME-00610 is an experimental immunotherapy drug that targets a new immune checkpoint molecule called CD200R1.
Since this drug is still in the clinical trial phase, it has the placeholder name 23ME-00610 rather than a commercial trade name.
This is a phase 1/2 study that will investigate the safety and effectiveness of 23ME-00610 in patients with several different cancer types, including kidney cancer.
In order to maximize effectiveness and minimize side effects, different doses of the drug will be used to determine the optimal dosage of these medications.
This is a single-group study, so there is no randomization, no placebo, and all eligible patients will receive treatment.
- Clear cell kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- No further drug therapies are available or recommended
Additional eligibility criteria will apply. Please speak to your doctor.Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreThe Hospital for Sick Children||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOttawa Hospital Cancer Centre||Principal InvestigatorNot Given||LocationOttawa, ON||Trial StatusRecruiting|